No Data
No Data
BMO Sees BMRN, LEGN, SLN as Attractive M&A Targets
Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
6 analysts have shared their evaluations of Ionis Pharmaceuticals (NASDAQ:IONS) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates th
Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Raises Target Price to $53
Stifel analyst Paul Matteis maintains $Ionis Pharmaceuticals(IONS.US)$ with a hold rating, and adjusts the target price from $50 to $53.According to TipRanks data, the analyst has a success rate of 46
Ionis Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 10.46% Stifel $50 → $53 Maintains Hold 06/14/2024 — Bernstein Upgrades Underperform → Market P
Express News | Ionis Pharmaceuticals Inc : Stifel Raises Target Price to $53 From $50